Please sign in to follow a disease.
Hairy cell leukemia variant
MONDO:0017600Hairy Cell Leukemia variant (HCL-V) is defined as a rare and indolent form of small, mature, B-cell leukemia characterized by splenomegaly, an elevated white blood cell (WBC) count and hyper-cellular bone marrow. HCL-V is more aggressive and resistant to therapy than classical HCL (HCL-C).
Also known as: HCL-V, HCL-v, hairy cell leukemia variant, leukemic reticuloendotheliosis variant, prolymphocytic variant of HCL, prolymphocytic variant of hairy cell leukaemia, prolymphocytic variant of hairy cell leukemia
2038 clinical trials for this condition and its sub-types, 9 tagged with Hairy cell leukemia variant itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for rare leukemia: drug targets MEK gene in BRAF-Negative patients
Disease control Recruiting nowThis study tests a drug called binimetinib for people with hairy cell leukemia that does not have the common BRAF gene mutation. The drug targets a different gene, MEK, which is often altered in these patients. The goal is to see if it can shrink or control the cancer in 40 adult…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered immune cells take on rare leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment for hairy cell leukemia (HCL) that has come back or not responded to standard care. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. Up to 27 adults will receive chemo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New registry aims to unlock secrets of rare leukemia
Knowledge-focused Recruiting nowThis study creates a registry for people with hairy cell leukemia (HCL), a rare form of adult leukemia. Researchers will track disease course, treatments, infections, and patient-reported outcomes over time. The goal is to identify trends, improve care, and design future clinical…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC